News
CRVO
24.45
-0.85%
-0.21
Weekly Report: what happened at CRVO last week (0506-0510)?
Weekly Report · 1d ago
CervoMed: General form for registration of securities under the Securities Act of 1933
Press release · 3d ago
CERVOMED INC: FILES PROSPECTUS RELATED TO RESALE FROM TIME TO TIME, BY SELLING STOCKHOLDERS OF UP TO 5.1 MLN SHARES OF COMMON STOCK
Reuters · 3d ago
Weekly Report: what happened at CRVO last week (0429-0503)?
Weekly Report · 05/06 11:38
Weekly Report: what happened at CRVO last week (0422-0426)?
Weekly Report · 04/29 11:45
CervoMed Updates Stakeholders on Clinical and Financial Status
TipRanks · 04/23 12:13
Weekly Report: what happened at CRVO last week (0415-0419)?
Weekly Report · 04/22 11:32
Weekly Report: what happened at CRVO last week (0408-0412)?
Weekly Report · 04/15 11:23
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Canaccord Genuity boosted the price target for CervoMed Inc. The Walt Disney Company shares rose 1.1% to close at $118.38 on Friday. Susquehanna increased the price targets for Transocean Ltd. And Sealed Air Corporation.
Benzinga · 04/08 12:00
CervoMed Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/08 11:48
CervoMed Price Target Raised to $65.00/Share From $50.00 by Canaccord Genuity
Dow Jones · 04/08 11:48
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
Benzinga · 04/08 11:37
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
TipRanks · 04/08 11:30
Weekly Report: what happened at CRVO last week (0401-0405)?
Weekly Report · 04/08 11:28
CERVOMED INC <CRVO.O>: CANACCORD GENUITY RAISES TARGET PRICE TO $65 FROM $50
Reuters · 04/08 05:27
CervoMed Shares Operational and Financial Insights Online
TipRanks · 04/04 11:12
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
Results from the phase 2b RewinD-LB study, using neflamapimod for the treatment of patients with dementia with Lewy bodies, are expected in the 2nd half of 2024. The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033. CervoMed is in the process of completing a private placement agreement to fund its operations through 2025.
Seeking Alpha · 04/02 06:59
CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
CervoMed's FY GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M. The company expects to be in a position to fund its operations through the end of 2024.
Seeking Alpha · 04/01 12:50
CERVOMED INC: PRO FORMA CASH AND CASH EQUIVALENTS FROM UPFRONT PROCEEDS EXPECTED TO PROVIDE RUNWAY THROUGH END OF 2025
Reuters · 04/01 12:00
Press Release: CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CervoMed reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates. Announced private placement of up to $149.4 million. Company on track to complete enrollment in 2Q 2024 in its RewinD-LB clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies.
Dow Jones · 04/01 12:00
More
Webull provides a variety of real-time CRVO stock news. You can receive the latest news about CervoMed through multiple platforms. This information may help you make smarter investment decisions.
About CRVO
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.